Apellis plots pegcetacoplan FDA filing in blockbuster GA use after revealing 18-month data

After posting mixed late-stage data last fall and securing FDA support to include midstage data in its approval application for pegcetacoplan in geographic atrophy (GA), Apellis has been awaiting one last set of results before proceeding to the agency. Now, with those 18-month data in hand, the company is getting its regulatory package together for a filing next quarter.